Zimmer Biomet Debuts WalkAI™ Artificial Intelligence Model to Predict Post-Operative Recovery Progress

WalkAI Adds Predictive Artificial Intelligence Capabilities to ZBEdge™ Connected Intelligence Suite, Offering Surgeons Data-Driven Guidance to Identify Patients with Lagging Gait Speed During Their Recovery

WARSAW, Ind., March 10, 2022 /PRNewswire/ — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the release of WalkAI™, a dynamic artificial intelligence (AI) model that identifies patients1 who are predicted to have a lower gait speed outcome at 90 days after hip or knee surgery. WalkAI, the company’s first AI-based solution, adds powerful predictive analytic capabilities to ZBEdge™, a suite of integrated smart, digital and robotic technologies purposefully engineered to deliver transformative data-powered clinical insights with the goal of improving patient outcomes.

WalkAI uses a proprietary algorithm to analyze a patient’s mobility to generate a personalized daily prediction of their gait (walking) speed at 90 days after surgery. The daily prediction is compared to anonymized, real-world data from the extensive ZBEdge database to identify when a patient’s recovery may not be on track based on predicted low gait speed.

“Using a proprietary, Zimmer Biomet-developed artificial intelligence algorithm, WalkAI is the orthopedic industry’s first and only AI-based model to create daily, personalized predictions and identify patients who may be exceptions to typical recovery curves in an effort to help surgeons mitigate or minimize poor outcomes,” said Liane Teplitsky, President, Global Robotics and Technology & Data Solutions, Zimmer Biomet. “WalkAI is built from our wealth of anonymized ZBEdge data and is the first model to demonstrate our unique capability to deliver actionable predictions by connecting real-world data and AI through ZBEdge products and experiences.”

WalkAI integrates with the mymobility® Care Management Platform, which collects patient gait data, through their iPhone®2 and when necessary, provides the WalkAI notification to healthcare professionals through the mymobility clinician dashboard.

“Our strategic prioritization and investment in R&D has solidified our position as an innovator in our space with breakthrough technologies like Persona IQ®, a first-to-world smart knee implant, mymobility Care Management Platform, ROSA® Robotics, and now, WalkAI, the first AI-based model in orthopedics to create daily personalized outcome predictions based on a patient’s gait recovery,” said Ivan Tornos, Chief Operating Officer, Zimmer Biomet. “ZBEdge is realizing our bold vision of an interconnected ecosystem of digital and robotic technologies by sharing data and unlocking clinical insights, which is now enhanced by artificial intelligence modeling.”

A first step for Zimmer Biomet’s AI platform, WalkAI has been rolled out globally to a select group of mymobility users and will be widely available as part of ZBEdge by the end of March 2022. For more information on WalkAI, visit

About the Company
Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.

With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation.

For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit or follow Zimmer Biomet on Twitter at

Cautionary Statement Regarding Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet’s expectations, plans, prospects, and product and service offerings, including new product launches and potential clinical successes. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see Zimmer Biomet’s periodic reports filed with the U.S. Securities and Exchange Commission (SEC). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet’s filings with the SEC. Forward-looking statements speak only as of the date they are made, and Zimmer Biomet disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this news release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this news release.

Apple and iPhone are registered trademarks of Apple, Inc.

1 Patients are assessed and identified by WalkAI from day 15 after surgery through day 40 after surgery.  During this time period it is predicting what their gait speed will be at day 90 after surgery.
2 WalkAI utilizes patient gait data collected for patients using the mymobility application on an iPhone. It is not supported for patients using mymobility on Android or through their browser.
Meredith Weissman
(703) 346-3127
Ezgi YagciKeri Mattox
(617) 549-2443(203) 399-0856

SOURCE Zimmer Biomet Holdings, Inc.

Image: Fictitious Patients and Data

Chris J. Stewart

Chris currently serves as President and CEO of Surgio Health. Chris has close to 20 years of healthcare management experience, with an infinity to improve healthcare delivery through the development and implementation of innovative solutions that result in improved efficiencies, reduction of unnecessary financial & clinical variation, and help achieve better patient outcomes. Previously, Chris was assistant vice president and business unit leader for HPG/HCA. He has presented at numerous healthcare forums on topics that include disruptive innovation, physician engagement, shifting reimbursement models, cost per clinical episode and the future of supply chain delivery.

Related Articles

Back to top button